UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2022

Commission File Number: 001-36891

Cellectis S.A.
(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):


EXHIBIT INDEX

Exhibit Title
       
99.1 Press release, dated March 3, 2022


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Cellectis S.A.    
  (Registrant)
   
  
Date: March 3, 2022     /s/ André Choulika    
  André Choulika
  Chief Executive Officer
  
EdgarFiling

EXHIBIT 99.1

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2021 Financial Results

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop potentially life-saving cell and gene therapies, announced its results for the fourth quarter of 2021, and full year ending December 31, 2021.

“In 2021, Cellectis presented encouraging preliminary data from patients who received fludarabine, cyclophosphamide and alemtuzumab preconditioning in the BALLI-01 study at the American Society of Hematology (ASH) 2021 annual meeting. BALLI-01 supports our mission to develop products for patients who remain in dire need of effective treatment options. These results showed that our preconditioning regimen, that included alemtuzumab, was well tolerated and promoted the expansion and clinical activity of UCART22 in patients with advanced B-cell Acute Lymphoblastic Leukemia. Both our Raleigh and Paris manufacturing facilities are now fully operational, with Paris producing plasmids, mRNA and viral vectors, and Raleigh manufacturing UCART22 and UCART20x22.” said Dr. André Choulika, CEO of Cellectis.

“In 2022, we are focusing on patient recruitment into our three ongoing Phase 1 clinical trials BALLI-01, AMELI-01, MELANI-01, (evaluating UCART22, UCART123, and UCARTCS1 respectively) and plan to file an investigational new drug application (IND) in the U.S. for our first allogeneic dual CAR T-cell therapy, UCART20x22. To further support our clinical trials, and with both manufacturing sites now fully operational, we will start dosing patients with investigational medicinal products made in-house.”

________________________
1 Cash position includes cash, cash equivalent, current financial assets and restricted cash. Restricted cash was $5million as of December 31, 2021.

Pipeline highlights

UCART Clinical Development Programs

BALLI-01 (evaluating UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

AMELI-01 (evaluating UCART123) in relapsed or refractory acute myeloid leukemia (r/r AML)

MELANI-01 (evaluating UCARTCS1) in relapsed or refractory multiple myeloma (r/r MM)

UCART Preclinical Programs

UCART20x22 in relapsed or refractory non hodgkin’s lymphoma (r/r NHL)

Licensed Allogeneic CAR-T Cell Development Programs

Allogene Therapeutics, Inc.’s CAR T programs utilize Cellectis technologies. ALLO-501 and ALLO-501A are anti-CD19 products being jointly developed under a collaboration agreement between Servier and Allogene based on an exclusive license granted by Cellectis to Servier. Servier grants to Allogene exclusive rights to ALLO-501 and ALLO-501A in the U.S. while Servier retains exclusive rights for all other countries. Allogene’s anti-BCMA and anti-CD70 programs are licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to these programs. 

On January 10, 2022, Allogene announced that the U.S. Food and Drug Administration (FDA) had removed the clinical hold on all of Allogene’s clinical trials which had been announced on October 7, 2021. After extensive investigation by Allogene, it was determined that the chromosomal abnormality detected in a single patient treated with ALLO-501A was unrelated to TALEN® gene editing or Allogene’s manufacturing process and had no clinical significance.

Servier and Allogene: anti-CD19 programs 

Allogene: anti-BCMA and anti-CD70 programs 

Manufacturing Facilities

Partnerships

Cytovia Therapeutics

2021 Corporate Highlights

Cellectis’ Innovation Days

In May 2021, Cellectis held a week-long virtual event, providing an inside look into the Company’s current and new product candidates pipeline, manufacturing and technologies. To watch a replay of all Cellectis Innovation Days episodes, click here.

Appointments

ATM program

2021 Financial Results

The condensed consolidated financial statements of Cellectis, which consolidate the results of Calyxt, Inc. of which Cellectis is a 61.8% stockholder (as of December 31, 2021) and 56.1% as of March 3, 2022, have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board (“IFRS”).

We present certain financial metrics broken out between our two reportable segments – Therapeutics and Plants – in the appendices of this Q4 2021 and Full Year 2021 financial results press release.

Fourth Quarter and Full Year 2021 Financial Results

Cash: As of December 31, 2021, Cellectis, including Calyxt, had $191 million in consolidated cash, cash equivalents, current financial assets and restricted cash of which $177 million are attributable to Cellectis on a stand-alone basis. This compares to $274 million in consolidated cash, cash equivalents, current financial assets and restricted cash as of December 31, 2020, of which $244 million was attributable to Cellectis on a stand-alone basis. This net decrease of $83 million primarily reflects (i) $116 million of net cash flows used in operating, investing and lease financing activities of Cellectis, (ii) $20 million of net cash flows used in operating, capital expenditures and lease financing activities of Calyxt and (iii) $6 million of unfavorable FOREX impact which was partially offset by (iv) $49 million of equity proceeds raised from sales under the Company’s “At-The-Market” (ATM) program in April 2021 and Calyxt ATM program during the fourth quarter of 2021 and (v) $10 million of proceeds from stock options exercises at Cellectis. Based on the current operating plan and financial projections, Cellectis excluding Calyxt anticipates that the cash, cash equivalents, and restricted cash of $177 million as of December 31, 2021 will fund its operations into early 2024.        

Revenues and Other Income: Consolidated revenues and other income were $14 million for the three months ended December 31, 2021 compared to $16 million for the three months ended December 31, 2020. Consolidated revenues and other income were $67 million for the year ended December 31, 2021 compared to $82 million for the year ended December 31, 2020. 58% of consolidated revenues and other income was attributable to Cellectis in the full year of 2021. This decrease between the year ended December 31, 2021 and 2020 was mainly attributable to a $29 million upfront payment received in March 2020 and the recognition of $20 million of other previously-received upfront and milestone payments on the five released targets based on the March 2020 amendment of the License, Development and Commercialization Agreement signed with Servier. That was partially offset by (i) the recognition of a $20.0 trade receivable obtained as consideration for a license granted to Cytovia, (ii) $10.0 million related to the recognition of two Allogene milestones, (iii) the increase in sales of soybean products at Calyxt for $4 million, and (iv) Calyxt’s Paycheck Protection Program loan forgiveness obtained in April 2021 for 1.5 million, and is partially offset by a decrease in licenses revenues of $2 million.

Cost of Revenues: Consolidated cost of revenues were $2 million for the three months ended December 31, 2021 compared to $19 million for the three months ended December 31, 2020. Consolidated cost of revenues was $31 million for the year ended December 31, 2021 compared to $36 million for the year ended December 31, 2020. This decrease was primarily explained by the cost of products sold during the period by Calyxt.

R&D Expenses: Consolidated R&D expenses were $32 million for the three months ended December 31, 2021 compared to $23 million for the three months ended December 31, 2020. Consolidated R&D expenses were $129 million for the year ended December 31, 2021 compared to $87 million for the year ended December 31, 2020. 91% of consolidated R&D expenses was attributable to Cellectis in the full year of 2021. The $42 million increase between the full year of 2021 and 2020 was primarily attributable to (i) higher wages and salaries and social charges on stock option grants of $14 million, to (ii) higher purchases, external and other expenses of $25 million and to (iii) higher non-cash stock-based compensation expenses of $3 million.

SG&A Expenses: Consolidated SG&A expenses were $10 million for the three months ended December 31, 2021 compared to $12 million for the three months ended December 31, 2020. Consolidated SG&A expenses were $38 million for the year ended December 31, 2021 compared to $44 million for the year ended December 31, 2020. 60% of consolidated SG&A expenses was attributable to Cellectis in the full year of 2021. The $6 million decrease was mainly attributable to lower non-cash stock-based compensation expenses of $6 million and a decrease in wages and salaries of $1 million partially offset by an increase in social charges on stock option grants and purchases, external expenses and other of $1 million.

Net Income (loss) Attributable to Shareholders of Cellectis: The consolidated net loss attributable to shareholders of Cellectis was $25 million (or $0.55 per share) for the three months ended December 31, 2021, of which $21 million was attributed to Cellectis, compared to $41 million (or $0.95 per share) for the three months ended December 31, 2020, of which $34 million was attributed to Cellectis. The consolidated net loss attributable to shareholders of Cellectis was $114 million (or $2.55 per share) for the year ended December 31, 2021, of which $97 million loss was attributed to Cellectis, compared to a loss of $81 million (or $1.91 per share) for the year ended December 31, 2020, of which $54 million was attributable to Cellectis. This $33 million increase in net loss between full year 2021 and 2020 was primarily driven by a decrease in revenues and other income of $15 million and by an increase in operating expenses of $30 million and a decrease in non controlling interests of $5 million partially offset a by $18 million increase in net financial gain.

Adjusted Net Income (Loss) Attributable to Shareholders of Cellectis: The consolidated adjusted net loss attributable to shareholders of Cellectis was $22 million (or $0.48 per share) for the three months ended December 31, 2021, of which $19 million is attributed to Cellectis, compared to a net loss of $37 million (or $0.88 per share) for the three months ended December 31, 2020, of which $31 million was attributed to Cellectis. The consolidated adjusted net loss attributable to Shareholders of Cellectis was $102 million (or $2.27 per share) for the year ended December 31, 2021, of which $85 million loss was attributable to Cellectis, compared to a loss of $67 million (or $1.57 loss per share) for the year ended December 31, 2020, of which $44 million was attributable to Cellectis.

Please see "Note Regarding Use of Non-GAAP Financial Measures" for reconciliation of GAAP net income (loss) attributable to shareholders of Cellectis to adjusted net income (loss) attributable to shareholders of Cellectis.

We currently foresee focusing our cash spending at Cellectis for 2022 in the following areas:

CELLECTIS S.A.
STATEMENT OF CONSOLIDATED FINANCIAL POSITION
($ in thousands, except per share data)

    As of
      December 31, 2020 December 31, 2021
   
       
ASSETS      
Non-current assets      
Intangible assets   1,584  1,854 
Property, plant, and equipment   71,673  78,846 
Right-of-use assets  73,845  69,423 
Other non-current financial assets   7,007  6,524 
Total non-current assets  154,109 156,647 
     
Current assets      
Inventories  1,606  - 
Trade receivables   5,171  20,361 
Subsidies receivables  10,703  9,268 
Other current assets   29,643  9,665 
Cash and cash equivalent and Current financial assets  268,239  186,135 
Total current assets   315,362  225,429 
TOTAL ASSETS   469,471 382,076 
       
LIABILITIES      
Shareholders’ equity     
Share capital   2,785  2,945 
Premiums related to the share capital      872,134  934,696 
Currency translation adjustment   (4,089) (18,021)
Retained earnings     (505,961) (584,129)
Net income (loss)     (81,074) (114,197)
Total shareholders’ equity - Group Share     283,795 221,293 
Non-controlling interests     25,051  15,181 
Total shareholders’ equity     308,846 236,474 
       
Non-current liabilities         
Non-current financial liabilities     28,836  20,030 
Non-current lease debts     75,764  71,526 
Non-current provisions   4,010  4,073 
Other non-current liabilities    -  626 
Total non-current liabilities      108,610 96,254 
        
Current liabilities         
Current financial liabilities     2,354 
Current lease debts   6,696  8,329 
Trade payables      24,609  23,762 
Deferred revenues and deferred income   452  301 
Current provisions   1,131  871 
Other current liabilities      19,127  13,731 
Total current liabilities      52,015 49,348 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY      469,471 382,076 

CELLECTIS S.A.
STATEMENT OF CONSOLIDATED OPERATIONS Fourth quarter
(unaudited)
($ in thousands, except per share data)

  For the three-month periods ended December 31, 2021
   2020  2021 
     
Revenues and other income     
Revenues 13,649  12,205 
Other income 1,983  1,458 
Total revenues and other income 15,632  13,663 
Operating expenses    
Cost of revenue (18,644) (2,247)
Research and development expenses (23,395) (32,367)
Selling, general and administrative expenses (12,490) (9,976)
Other operating income (expenses) (267) 5 
Total operating expenses (54,796) (44,585)
     
Operating income (loss) (39,164) (30,922)
     
Financial gain (loss) (7,567) 2,842 
     
Net income (loss) (46,730) (28,080)
Attributable to shareholders of Cellectis (40,607) (24,996)
Attributable to non-controlling interests (6,123) (3,084)
     
Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (0.95) (0.55)
     
Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (0.95) (0.55)

CELLECTIS S.A.
STATEMENT OF CONSOLIDATED OPERATIONS Full Year
($ in thousands, except per share data)

  For the year ended December 31,
   2020  2021 
     
Revenues and other income     
Revenues 73,949  57,293 
Other income 8,507  9,778 
Total revenues and other income 82,456  67,071 
Operating expenses    
Cost of revenue (36,275) (31,360)
Research and development expenses (86,950) (129,030)
Selling, general and administrative expenses (44,201) (37,869)
Other operating income (expenses) (467) 511 
Total operating expenses (167,893) (197,748)
     
Operating income (loss) (85,437) (130,677)
     
Financial gain (loss) (12,046) 5,570 
     
Net income (loss) (97,483) (125,107)
Attributable to shareholders of Cellectis (81,074) (114,197)
Attributable to non-controlling interests (16,409) (10,910)
     
Basic net income (loss) attributable to shareholders of Cellectis per share ($/share) (1.91) (2.55)
     
Diluted net income (loss) attributable to shareholders of Cellectis per share ($/share) (1.91) (2.55)

CELLECTIS S.A.

DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE SEGMENTS Fourth Quarter
(unaudited) - ($ in thousands)

 For the three-month period ended December 31, 2020  For the three-month period ended December 31, 2021 
$ in thousands Plants Therapeutics Total reportable segments  Plants Therapeutics Total reportable segments 
        
External revenues  13,424 225 13,649  1,943 10,262 12,205 
External other income  - 1,983 1,983  - 1,458 1,458 
External revenues and other income 13,424 2,208 15,632  1,943 11,720 13,663 
Cost of revenue (18,258)(386)(18,644) (2,004)(243)(2,247)
Research and development expenses (2,508)(20,887)(23,395) (2,832)(29,535)(32,367)
Selling, general and administrative expenses (5,449)(7,041)(12,490) (3,467)(6,509)(9,976)
Other operating income and expenses (17)(250)(267) (2)7 5 
Total operating expenses (26,232)(28,564)(54,796) (8,305)(36,280)(44,585)
Operating income (loss) before tax (12,808)(26,356)(39,164)(6,362)(24,560)(30,922)
Financial gain (loss) (270)(7,297)(7,567) (287)3,129 2,842 
Net income (loss)  (13,078)(33,652)(46,730)(6,649)(21,431)(28,080)
Non controlling interests 6,123 - 6,123  3,084 - 3,084 
Net income (loss) attributable to shareholders of Cellectis (6,955)(33,652)(40,607)(3,565)(21,431)(24,997)
R&D non-cash stock-based expense attributable to shareholder of Cellectis 247 1,785 2,032  228 2,459 2,686 
SG&A non-cash stock-based expense attributable to shareholder of Cellectis 580 529 1,109  303 211 514 
Adjustment of share-based compensation attributable to shareholders of Cellectis 827 2,314 3,141  530 2,670 3,200 
Adjusted net income (loss) attributable to shareholders of Cellectis (6,128)(31,338)(37,466)(3,035)(18,761)(21,796)
Depreciation and amortization (653)(2,593)(3,246) (279)(2,461)(2,740)
Additions to tangible and intangible assets 887 7,477 8,364  811 1,005 1,816 

CELLECTIS S.A.
DETAILS OF KEY PERFORMANCE INDICATORS BY REPORTABLE
SEGMENTS Full Year
- ($ in thousands)

 For the year ended December 31, 2020 For the year ended December 31, 2021
($ in thousands) PlantsTherapeuticsTotal reportable segments PlantsTherapeuticsTotal reportable segments
        
External revenues22,892 51,057 73,949  26,946 30,347 57,293 
External other income- 8,507 8,507  1,528 8,250 9,778 
External revenues and other income22,892 59,564 82,456  28,475 38,597 67,071 
Cost of revenue(34,324)(1,951)(36,275) (29,517)(1,844)(31,360)
Research and development expenses(9,903)(77,048)(86,951) (11,190)(117,840)(129,030)
Selling, general and administrative expenses(21,688)(22,513)(44,201) (14,987)(22,882)(37,869)
Other operating income and expenses(103)(363)(466) 23 488 511 
Total operating expenses(66,018)(101,875)(167,893) (55,671)(142,077)(197,748)
Operating income (loss) before tax(43,126)(42,311)(85,437) (27,196)(103,481)(130,677)
Net financial gain (loss)(776)(11,270)(12,046) (1,162)6,731 5,570 
Net income (loss) (43,902)(53,581)(97,483) (28,358)(96,749)(125,107)
Non-controlling interests16,409 - 16,409  10,910 - 10,910 
Net income (loss) attributable to shareholders of Cellectis(27,493)(53,581)(81,074) (17,448)(96,749)(114,197)
R&D non-cash stock-based expense attributable to shareholder of Cellectis801 6,790 7,591  909 9,381 10,290 
SG&A non-cash stock-based expense attributable to shareholder of Cellectis3,536 3,238 6,774  95 2,113 2,207 
Adjustment of share-based compensation attributable to shareholders of Cellectis4,337 10,028 14,365  1,004 11,493 12,497 
Adjusted net income (loss) attributable to shareholders of Cellectis(23,156)(43,553)(66,709) (16,444)(85,256)(101,700)
Depreciation and amortization tangible and intangible assets(1,869)(7,950)(9,819) (1,208)(6,371)(7,579)
Additions to tangible and intangible assets1,786 48,813 50,599  1,187 15,451 16,638 

Note Regarding Use of Non-IFRS Financial Measures
Cellectis S.A. presents adjusted net income (loss) attributable to shareholders of Cellectis in this press release. Adjusted net income (loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We have included in this press release a reconciliation of this figure to net income (loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS. Because adjusted net income (loss) attributable to shareholders of Cellectis excludes Non-cash stock-based compensation expense—a non-cash expense, we believe that this financial measure, when considered together with our IFRS financial statements, can enhance an overall understanding of Cellectis’ financial performance. Moreover, our management views the Company’s operations, and manages its business, based, in part, on this financial measure. In particular, we believe that the elimination of Non-cash stock-based expenses from Net income (loss) attributable to shareholders of Cellectis can provide a useful measure for period-to-period comparisons of our core businesses. Our use of adjusted net income (loss) attributable to shareholders of Cellectis has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under IFRS. Some of these limitations are: (a) other companies, including companies in our industry which use similar stock-based compensation, may address the impact of Non-cash stock- based compensation expense differently; and (b) other companies may report adjusted net income (loss) attributable to shareholders or similarly titled measures but calculate them differently, which reduces their usefulness as a comparative measure. Because of these and other limitations, you should consider adjusted net income (loss) attributable to shareholders of Cellectis alongside our IFRS financial results, including Net income (loss) attributable to shareholders of Cellectis.

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME Fourth Quarter

(unaudited)
($ in thousands, except per share data)

  For the three-month periods ended December 31, 2021 
    2020     2021  
        
Net income (loss) attributable to shareholders of Cellectis    (40,607)(24,996)
Adjustment: 
      Non-cash stock-based compensation expense attributable to shareholders of Cellectis  
 3,141  3,200 
Adjusted net income (loss) attributable to shareholders of Cellectis  (37,466)(21,796)
     
Basic Adjusted  net income (loss) attributable to shareholders of Cellectis ($/share)  (0.88) (0.48)
     
Weighted average number of outstanding shares, basic (units) (1)  42,589,496 45,481,310 
     
Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1)  (0.88) (0.48)
     
Weighted average number of outstanding shares, diluted (units) (1)  42,589,496 45,481,310 

(1) When we have adjusted net loss, in accordance with IFRS, we use the Weighted average number of outstanding shares, basic to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share). When we have adjusted net income, in accordance with IFRS, we use the weighted average number of outstanding shares, diluted to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share).

RECONCILIATION OF GAAP TO NON-GAAP NET INCOME Full Year
(unaudited)
($ in thousands, except per share data)

  For the year ended December 31,
  2020  2021 
      
Net income (loss) attributable to shareholders of Cellectis  (81,074) (114,197)
Adjustment:       
Non-cash stock-based compensation expense attributable to shareholders of Cellectis
 14,365  12,497 
Adjusted net income (loss) attributable to shareholders of Cellectis(66,709) (101,700)
     
Basic Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1.57) (2.27)
     
Weighted average number of outstanding shares, basic (units) (1)42,503,447  44,820,279 
     
Diluted Adjusted net income (loss) attributable to shareholders of Cellectis ($/share) (1) (1.57) (2.27)
     
Weighted average number of outstanding shares, diluted (units) (1)42,503,447  44,820,279 

(1) When we have adjusted net loss, in accordance with IFRS, we use the Weighted average number of outstanding shares, basic to compute the Diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share). When we have adjusted net income, in accordance with IFRS, we use the weighted average number of outstanding shares, diluted to compute the diluted adjusted net income (loss) attributable to shareholders of Cellectis ($/share).

Conference Call and Webcast Details
Cellectis will host a live conference call and live audio webcast on March 4th, 2022 at 8AM EDT / 2:00PM CET to discuss fourth quarter and full year 2021 results and provide a business update.

Dial-In Information 
Live (US/Canada): + 1(877) 451-6152 
Live (international): + 1(201) 389-0879 
Conference ID: 13727032  

Webcast 
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1528796&tp_key=c23a20c39e

The webcast audio will be made available for one year on Cellectis’ website, linked here.

About Cellectis 
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs.  
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.  
Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).  

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

For more information, visit www.cellectis.com     
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact: 

Media contacts: 
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300 

Investor Relation contact: 
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Forward-looking Statements   
This press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,” “could” and “will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our licensed partners Servier and Allogene. Forward-looking statements include statements about  advancement, timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the timing of our presentation of data and submission of regulatory filings, the adequacy of our supply  of clinical vials, the  operational capabilities at our manufacturing facilities, and the sufficiency of cash to fund operation. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development as well as the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2020 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. 

Attachments